Abstract
The soluble triggering receptor expressed on myeloid cells 1 (sTREM-1) is a useful marker of infection in patients with sepsis, but has not been adequately evaluated in patients with chemotherapy-associated febrile neutropenia (FN). The value of sTREM-1 in this setting has been tested in a retrospective, pilot study using stored serum from 48 cancer patients with documented FN. On presentation, patients were categorized according to the Talcott risk-index clinical score. Circulating soluble sTREM-1 was measured using an ELISA procedure, while procalcitonin (PCT) or interleukins 6 (IL-6) and 8 (IL-8), included for comparison, were measured using an immunoluminescence-based assay and Bio-Plex® suspension bead array system, respectively. Circulating concentrations of both sTREM-1 and PCT were significantly (P < 0.05) elevated in patients at high risk for complications or death, as predicted by the Talcott score and were significantly lower in patients who responded to empiric antimicrobial agents. Neither IL-6 nor IL-8 accurately predicted serious complications in patients with FN. These observations, albeit from a pilot study, demonstrate that sTREM-1 is indeed elevated in high-risk patients with FN and is potentially useful to predict their clinical course, either together with, or as an alternative to PCT.
Similar content being viewed by others
References
Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266
Talcott JA, Finberg R, Mayer RJ et al (1988) The medical course of cancer patients with fever and neutropenia. Arch Int Med 148:2561–2568
Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott JA (2000) The multinational association for supportive care in cancer risk-index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051
Nakagawa Y, Suzuki K, Masaoka T (2009) Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. J Infect Chemother 15:174–179
Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K (2008) The role of procalcitonin in febrile neutropenic patients: review of the literature. Infection 36:396–407
Jimeno A, Garcia-Velasso A, del Val O, González-Billalabeitia E, Hernando S, Hernández R, Sánchez-Muňoz A, López-Martin A, Durán I, Robles L, Cortes-Funes H, Paz-Ares L (2004) Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. Cancer 100:2462–2469
Uys A, Rapoport BL, Fickl H, Meyer PWA, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1β, -6, -8 and -10. Eur J Cancer Care 16:475–483
Persson L, Söderquist B, Engervall P, Vikerfors T, Hansson L-O, Tidefelt U (2005) Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. Eur J Haematol 74:297–303
Massaro KSR, Costa SF, Leone C, Chamone DAF (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137. doi:10,1186/1471-2334-7-137
Prat C, Sancho JM, Dominguez J, Xicoy B, Giminez m, Ferra C, Blanco S, Lacoma A, Ribera JM, Aurina V (2008) Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. Leuk Lymphoma 49:1752–1761
Semeraro M, Thomée C, Rolland E, Le Deley MC, Rosselini D, Troalen F, Amoroso L, Drubel M, Hartmann O (2010) A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. Pediatr Blood Cancer 54:284–290
Schultz MJ, Determann RM (2008) PCT and sTREM-1: the markers of infection in critically-ill patients? Med Sci Monit 14:RA241–RA247
Ford JW, McVicar DW (2009) TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 21:1–9
Jiyong J, Tiancha H, Wei C, Huahao S (2009) Diagnostic value of the soluble triggering receptor expressed on myeloid cells-1 in bacterial infection: a meta-analysis. Intensive Care Med 35:587–595
Tejera A, Santolaria F, Diez M-L, Alemán-Valls M-R, Gonzáles-Reimers E, Martínez-Riera A, Milena-Abril A (2007) Prognosis of community acquired pneumonia (CAP): value of triggering receptor expressed on myeloid cells-1 (TREM-1) and other mediators of the inflammatory response. Cytokine 38:117–123
Lin CH, Ho CC, Yao M, Hsu SC, Yu CJ (2009) sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) as marker indicating infection in patients with neutropenic fever. Am J Respir Crit Care Med 179:A4704
Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer risk-index score. Support Care Cancer 12:555–560
Giamarellou H, Giamarellos-Bourboulis EJ, Repoussis P et al (2004) Potential use of procalcitonin as a diagnostic criterion in febrile neutropenia: experience from a multicenter study. Clin Microbiol Infect 10:628–633
Stryjewski GR, Nylen ES, Bell MJ et al (2005) Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. Pediatr Crit Care Med 6:129–135
Porfyridis I, Plachouras D, Karagianni V, Kotanidou A, Papiris SA, Giamarellou H, Giamarellos-Bourboulis EJ (2010) Diagnostic value of triggering receptor expressed on myeloid cells-1 and C-reactive protein for patients with lung infiltrates: an observational study. BMC Infect Dis 10:286–295
Talcott JA, Whalen A, Clark J et al (1994) Home antibiotic therapy for low risk cancer patients with fever and neutropenia: a pilot study of 30 patients based on a validated prediction rule. J Clin Oncol 12:107–114
Lav RC, King SM, Richardson SE (1994) Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Pediatr Hematol Oncol 11:417–421
Talcott JA, Siegel RD, Finberg R et al (1992) Risk assessment in cancer patients with fever and neutropenia. A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322
Han YY, Doughty LA, Kofos D, Sasser H, Carcillo JA (2003) Procalcitonin is persistently increased among children with poor outcome from bacterial sepsis. Pediatr Crit Care Med 4:21–25
Sarmati L, Beltrame A, Dori L, Maffongelli G, Cudillo L, De Angelis G, Picardi A, Ottaviani L, Cefalo MG, Venditti A, Amadori S, Arcese W, Andreoni M (2010) Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. Am J Hematol 85(5):380–383
Kelso A (1998) Cytokines: principles and prospects. Immunol Cell Biol 76:300–317
Yamamura M, Uyemura K, Deans RJ et al (1991) Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254:277–279
Hakim H, Flynn PM, Srivastava DK, Knapp KM, Li C, Okuma J, Gaur AH (2010) Risk prediction in pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J 29:53–59
Karapanagiotou EM, Pelekanou E, Charpidou A et al (2008) Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. Anticancer Res 28:1411–1416
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
ESM 1
(PDF 34 kb)
Rights and permissions
About this article
Cite this article
Kwofie, L., Rapoport, B.L., Fickl, H. et al. Evaluation of circulating soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) to predict risk profile, response to antimicrobial therapy, and development of complications in patients with chemotherapy-associated febrile neutropenia: a pilot study. Ann Hematol 91, 605–611 (2012). https://doi.org/10.1007/s00277-011-1339-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-011-1339-4